How does VIMIAN BTA's PS Ratio compare to its peers?

VIMIAN BTA is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (9.2x).

How does VIMIAN BTA's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

VIMIAN BTA is good value based on its Price-To-Sales Ratio (4.5x) compared to the Swedish Medical Equipment industry average (4.6x).

What is VIMIAN BTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate VIMIAN BTA's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of VIMIAN BTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

VIMIAN BTA (SEK32.8) is trading below our estimate of [[fair value]] (SEK55.58)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

VIMIAN BTA Stock Overview

Engages in the animal health business worldwide. More details

VIMIAN BTA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	3/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 41% below our estimate of its fair value

Earnings are forecast to grow 48.72% per year

Became profitable this year

Risk Analysis

Interest payments are not well covered by earnings

Shares are highly illiquid

Shareholders have been diluted in the past year

My Notes

Capture your thoughts, links and company narrative

Vimian Group AB (publ) Competitors

Xvivo Perfusion

OM:XVIVO

SEK 16.2b

OssDsign

OM:OSSD

SEK 1.0b

Bactiguard Holding

OM:BACTI B

SEK 1.3b

Elekta

OM:EKTA B

SEK 23.6b

Price History & Performance

Summary of share price highs, lows and changes for Vimian Group
Historical stock prices
Current Share Price	SEK 32.80
52 Week High	SEK 33.70
52 Week Low	SEK 31.60
Beta	1.52
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	2.50%

Recent updates

Shareholder Returns

	VIMIAN BTA	SE Medical Equipment	SE Market
7D	0.3%	0.4%	0.7%
1Y	n/a	-9.4%	6.3%

Return vs Industry: Insufficient data to determine how VIMIAN BTA performed against the Swedish Medical Equipment industry.

Return vs Market: Insufficient data to determine how VIMIAN BTA performed against the Swedish Market.

Price Volatility

Is VIMIAN BTA's price volatile compared to industry and market?
VIMIAN BTA volatility
VIMIAN BTA Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.5%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: VIMIAN BTA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine VIMIAN BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2020	1,000	Patrik Eriksson	vimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

Vimian Group AB (publ) Fundamentals Summary

How do Vimian Group's earnings and revenue compare to its market cap?
VIMIAN BTA fundamental statistics
Market cap	SEK 17.00b
Earnings (TTM)	SEK 113.35m
Revenue (TTM)	SEK 3.82b

150.0x

P/E Ratio

4.5x

P/S Ratio

Is VIMIAN BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIMIAN BTA income statement (TTM)
Revenue	€331.73m
Cost of Revenue	€102.30m
Gross Profit	€229.43m
Other Expenses	€219.59m
Earnings	€9.84m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)	0.019
Gross Margin	69.16%
Net Profit Margin	2.97%
Debt/Equity Ratio	57.4%

How did VIMIAN BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/04/11 03:10
End of Day Share Price	2024/04/11 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vimian Group AB (publ) is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Blanka Porkolab	Barclays
Hassan Al-Wakeel	Barclays
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB

Vimian Group OM:VIMIAN BTA Stock Report